Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danilo Fliser

Showing results (31-40 of 293) with videos related to

Pageof 30
Sort By:
European Journal of Clinical Investigation|June 11, 2010
Effect of experimental hyperglycaemia on renal haemodynamics in prediabetic patients with and without AT1 receptor blockadeHelga Frank, Stefan Pscherer, Danilo Fliser, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 24, 2015
Ferric pyrophosphate: good things come to those who wait?Lisa H Fell, Danilo Fliser, Gunnar H Heine
Journal of the American Society of Nephrology : JASN|October 29, 2000
Opposing effects of angiotensin II on muscle and renal blood flow under euglycemic conditionsDanilo Fliser, Ralf Dikow, Sadri Demukaj, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 11, 2015
Innate immunity in CKD-associated vascular diseasesStephen Zewinger, Timo Schumann, Danilo Fliser, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 11, 2017
Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trialDanilo Fliser, Frank Dellanna, Michael Koch, et al.
The New England Journal of Medicine|November 4, 2011
Bardoxolone methyl, chronic kidney disease, and type 2 diabetesKyrill S Rogacev, Jörg T Bittenbring, Danilo Fliser
Clinical Nephrology|May 16, 2013
Mycobacterium fortuitum peritonitis in peritoneal dialysis and its effects on the peritoneumStephen Zewinger, Clemens-Magnus Meier, Danilo Fliser, et al.
Nature Reviews. Nephrology|September 29, 2020
WNT-β-catenin signalling - a versatile player in kidney injury and repairStefan J Schunk, Jürgen Floege, Danilo Fliser, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 17, 2010
Wormwood (Artemisia absinthium) for poorly responsive early-stage IgA nephropathy: a pilot uncontrolled trialSimone Krebs, Bilal Omer, Talib Noor Omer, et al.
Nature Clinical Practice. Cardiovascular Medicine|September 23, 2006
Mechanisms of disease: erythropoietin--an old hormone with a new mission?Danilo Fliser, Ferdinand H Bahlmann, Kirsten deGroot, et al.
Pageof 30

Showing results (31-40 of 293) with videos related to

Sort By:
Pageof 30
European Journal of Clinical Investigation|June 11, 2010
Effect of experimental hyperglycaemia on renal haemodynamics in prediabetic patients with and without AT1 receptor blockadeHelga Frank, Stefan Pscherer, Danilo Fliser, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 24, 2015
Ferric pyrophosphate: good things come to those who wait?Lisa H Fell, Danilo Fliser, Gunnar H Heine
Journal of the American Society of Nephrology : JASN|October 29, 2000
Opposing effects of angiotensin II on muscle and renal blood flow under euglycemic conditionsDanilo Fliser, Ralf Dikow, Sadri Demukaj, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 11, 2015
Innate immunity in CKD-associated vascular diseasesStephen Zewinger, Timo Schumann, Danilo Fliser, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 11, 2017
Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trialDanilo Fliser, Frank Dellanna, Michael Koch, et al.
The New England Journal of Medicine|November 4, 2011
Bardoxolone methyl, chronic kidney disease, and type 2 diabetesKyrill S Rogacev, Jörg T Bittenbring, Danilo Fliser
Clinical Nephrology|May 16, 2013
Mycobacterium fortuitum peritonitis in peritoneal dialysis and its effects on the peritoneumStephen Zewinger, Clemens-Magnus Meier, Danilo Fliser, et al.
Nature Reviews. Nephrology|September 29, 2020
WNT-β-catenin signalling - a versatile player in kidney injury and repairStefan J Schunk, Jürgen Floege, Danilo Fliser, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 17, 2010
Wormwood (Artemisia absinthium) for poorly responsive early-stage IgA nephropathy: a pilot uncontrolled trialSimone Krebs, Bilal Omer, Talib Noor Omer, et al.
Nature Clinical Practice. Cardiovascular Medicine|September 23, 2006
Mechanisms of disease: erythropoietin--an old hormone with a new mission?Danilo Fliser, Ferdinand H Bahlmann, Kirsten deGroot, et al.
Pageof 30